Cardinal Health Reports First-quarter Results for Fiscal Year 2017

Go back to Cardinal Health Reports First-quarter Results for Fiscal Year 2017

Leerink Partners Cuts Price Target on Cardinal Health (CAH) Following 1Q

November 1, 2016 7:53 AM EDT

Leerink Partners maintained an Outperform rating on Cardinal Health (NYSE: CAH), and cut the price target to $80.00 (from $95.00), following the company's 1Q earnings report. Leerink cut EPS estimates for 2017 and 2018 by ~$0.15 and ~$0.20, respectively, due to the headwinds in the Pharmaceutical Division. On the call management stated that in 2Q the... More

Cardinal Health (CAH) Tops Q1 EPS by 3c; Lowers Guidance

October 31, 2016 7:04 AM EDT

Cardinal Health (NYSE: CAH) reported Q1 EPS of $1.24, $0.03 better than the analyst estimate of $1.21. Revenue for the quarter came in at $32 billion versus the consensus estimate of $31.04 billion.

GUIDANCE:

Cardinal Health sees FY2017 EPS of $5.40-$5.60, versus prior guidance of... More